ESMO Immuno-Oncology Congress 2017

Oncology Meeting Resources

07 Dec - 10 Dec 2017, Geneva, Switzerland

ESMO Immuno Oncology Congress 2017

ESMO Immuno Oncology Congress 2017 reflects ESMO’s commitment to providing oncologists who need to learn how to apply the latest research and standards of care in the immunotherapy of cancer with a comprehensive update in an environment rich with highly specialised professionals.

Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access.
Congress attendees should access via the ESMO Conferences platform.
Resources will be added as they become available.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme |Future ESMO meetings





Format available

http://oncologypro.esmo.org/Meeting-Resourc...xpression-and-associations-in-tumour-biology

Date: 07 Dec 2017
Presenter: Kurt Schalper
Topics: Colon Cancer, Rectal Cancer, Gastrointestinal Cancers, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...ession-as-a-predictive-and-prognostic-factor

Date: 07 Dec 2017
Presenter: Keith Kerr
Resources: Presentation, Webcast
Topics: Oesophageal Cancer, Gastrointestinal Cancers, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...unohistochemistry-Assays-LDTs-and-validation

Date: 07 Dec 2017
Presenter: Keith Miller

http://oncologypro.esmo.org/Meeting-Resourc...tigations-and-the-future-of-protein-analysis

Date: 07 Dec 2017
Presenter: Periklis Foukas
Resources: Presentation, Webcast
Topics: Basic Science, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...-1L-non-squamous-metastatic-NSCLC-IMpower150

BackgroundAtezolizumab (atezo; anti–PD-L1) inhibits PD-L1 binding to PD-1 and B7.1, restoring anti-cancer immunity. Bev may further enhance atezo efficacy by inhibiting VEGF immunosuppression and promoting T-cell tumour infiltration.

Date: 07 Dec 2017
Presenter: Martin Reck
Resources: Abstract, Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...ogy-Congress-2017/Invited-Discussant-LBA1_PR

Date: 07 Dec 2017
Presenter: Naiyer Rizvi
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...cts-of-VEGF-targeted-therapy-Fact-or-fiction

Date: 07 Dec 2017
Presenter: Thomas Powles
Resources: Presentation, Webcast
Topics: Gastric Cancer, Gastrointestinal Cancers, Lung and other Thoracic Tumours, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...enal-Cell-Carcinoma-mRCC-A-phase-1b-Trial-3O

BackgroundIL-10 is anti-inflammatory and stimulates the cytotoxicity and proliferation of CD8+ T cells at higher concentrations. IL-10 receptors and PD1 are expressed on activated and exhausted CD8 T...

Date: 08 Dec 2017
Presenter: Aung Naing
Resources: Abstract, Presentation, Webcast
Topics: Lymphomas, Haematologic Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...d-cells-in-the-tumor-microenvironment-TME-4O

BackgroundE7046 is a selective small molecule antagonist of the prostaglandin E2 receptor-type-4 that inhibits the differentiation of monocytic myeloid lineage cells towards a pro-tumorigenic phenotype in the TME.

Date: 08 Dec 2017
Presenter: Aparna Parikh
Resources: Abstract, Presentation, Webcast
Topics: Colon Cancer, Rectal Cancer, Gastrointestinal Cancers, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...neoantigens-for-the-treatment-of-melanoma-6O

BackgroundThe genome of cancer cells is inherently instable promoting multiple genomic alterations and epigenetic changes. This process leads to a unique molecular profile of every given tumor.

Date: 08 Dec 2017
Presenter: Matthias Miller
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Colon Cancer, Rectal Cancer, Gastrointestinal Cancers